| Alicia Vitek, NP-C | |
|
2010 S Arlington Heights Rd, Arlington Heights, IL 60005-4134 | |
| (847) 258-4978 | |
| Not Available |
| Full Name | Alicia Vitek |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 2010 S Arlington Heights Rd, Arlington Heights, Illinois |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093301541 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 209022407 (Illinois) | Primary |
| Entity Name | Signify Health Medical Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750845863 PECOS PAC ID: 2163764424 Enrollment ID: O20190507001451 |
News Archive
Research work drawn up by specialists from the Department of Plastic, Reconstructive and Aesthetic Surgery at the University of Navarra Hospital has shown that, after surgical treatment for facial paralysis through using muscular transplant and nervous transposition (connection of facial muscle to a nerve different from the injured facial nerve), the brain of a woman - in comparison to that of a male - manages to adapt itself better, recovers the spontaneous smile and has a greater time period available for repairing the paralysis.
Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.
People with type 1 diabetes are at high risk of developing kidney disease, but no therapies are proven to prevent impaired kidney function in these patients. In the Diabetes Control and Complications Trial (DCCT), Ian de Boer, MD and his team looked to see if intensive diabetes therapy aimed at reducing blood sugar as close to the normal range as possible might protect type 1 diabetics' kidney function. The study's results were presented during the American Society of Nephrology's Annual Kidney Week.
Seeking to improve the care of preterm infants, a new study by researchers at Rutgers Robert Wood Johnson Medical School has found a more accurate test for jaundice, a common disorder in newborns.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alicia Vitek, NP-C 2720 S River Rd, Ste 130, Des Plaines, IL 60018-4110 Ph: (630) 880-1682 | Alicia Vitek, NP-C 2010 S Arlington Heights Rd, Arlington Heights, IL 60005-4134 Ph: (847) 258-4978 |
News Archive
Research work drawn up by specialists from the Department of Plastic, Reconstructive and Aesthetic Surgery at the University of Navarra Hospital has shown that, after surgical treatment for facial paralysis through using muscular transplant and nervous transposition (connection of facial muscle to a nerve different from the injured facial nerve), the brain of a woman - in comparison to that of a male - manages to adapt itself better, recovers the spontaneous smile and has a greater time period available for repairing the paralysis.
Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.
People with type 1 diabetes are at high risk of developing kidney disease, but no therapies are proven to prevent impaired kidney function in these patients. In the Diabetes Control and Complications Trial (DCCT), Ian de Boer, MD and his team looked to see if intensive diabetes therapy aimed at reducing blood sugar as close to the normal range as possible might protect type 1 diabetics' kidney function. The study's results were presented during the American Society of Nephrology's Annual Kidney Week.
Seeking to improve the care of preterm infants, a new study by researchers at Rutgers Robert Wood Johnson Medical School has found a more accurate test for jaundice, a common disorder in newborns.
› Verified 8 days ago
Cayce Mcconnell, APN Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 901 W Kirchhoff Rd, Arlington Heights, IL 60005 Phone: 847-618-4180 Fax: 847-618-2709 | |
Mrs. Jessica R Anderson, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2010 S Arlington Heights Rd Ste 110, Arlington Heights, IL 60005 Phone: 847-258-4978 | |
Debra Lanette Luhrsen, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 121 S Wilke Rd Ste 600, Arlington Heights, IL 60005 Phone: 224-535-7155 | |
Sylwia Trninic, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 880 W Central Rd Ste 5000, Arlington Heights, IL 60005 Phone: 847-618-3800 Fax: 847-618-3809 | |
Ms. Pian Pian Moy, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 880 W Central Rd Ste 8200, Arlington Heights, IL 60005 Phone: 847-259-4482 Fax: 847-259-6406 | |
Dipa Patel, APRN, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1606 N Arlington Heights Rd, Arlington Heights, IL 60004 Phone: 847-797-8900 | |
Haley Glickman, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 800 W Central Rd, Arlington Heights, IL 60005 Phone: 847-618-5879 Fax: 847-618-7609 |